Navigation Links
Malaria medication may help against 1 type of frontotemporal dementia
Date:2/2/2011

Frontotemporal dementia is caused by a breakdown of nerve cells in the frontal and temporal region of the brain (fronto-temporal lobe), which leads to, among other symptoms, a change in personality and behavior. The cause of some forms of frontotemporal dementia is a genetically determined reduction of a hormone-like growth factor, progranulin. Scientists around Dr. Anja Capell and Prof. Christian Haass have now shown that various drugs that are already on the market to treat malaria, angina pectoris or heart rhythm disturbances can increase the production of progranulin. Accordingly, these drugs are good candidates for treatment of this specific form of frontotemporal dementia. The work will be published in the online edition of the scientific journal Journal of Neuroscience on February 2nd, 2011.

Progranulin is needed in the human brain as a protective factor for sensitive nerve cells, too little progranulin therefore results in a progressive neuronal cell death. As for almost every other gene, there are also two copies of the progranulin gene in the cell. In patients with progranulin dependent frontotemporal dementia, one of the two copies is defective, leading to a 50% reduction in progranulin levels. To rescue the lack of progranulin, the Munich researchers tested various substances for their ability to stimulate the remaining progranulin production and identified a drug called bafilomycin (BafA1). They then examined the molecular mechanism underlying the impact of BafA1 on progranulin more closely. Growth factors such as progranulin are produced in cellular membrane inclusions, known as vesicles. BafA1 has an alkalizing effect on these vesicles: After administration of BafA1 the interior of the vesicles is less acidic and this increases the production of progranulin.

This observation encouraged the researchers to investigate further alkalizing substances for their ability to raise progranulin levels. Among the substances that passed the test were three drugs that are already on the market to treat various diseases: a medication for angina pectoris (bepridil), one for heart rhythm problems (amiodarone) and the widely used malaria drug chloroquine. Chloroquine increased the progranulin level not only in experiments with mouse cells to normal, but also in cells from patients with the defective progranulin gene.

In a clinical study in collaboration with the University of London, the team of Prof. Haass and Dr. Capell will now investigate whether chloroquine actually helps against progranulin dependent frontotemporal dementia. The human studies can be started very soon, as chloroquine has been used on countless patients, so that serious side effects are not to be expected. Even though the Munich scientists are optimistic, Prof. Haass warns against exaggerated hopes. "Experience shows that the step from cell and animal models to the patient is always connected with considerable difficulties. It will take several years until we know, whether chloroquine can be used as therapy for progranulin dependent frontotemporal dementia," says Haass.


'/>"/>

Contact: Katrin Weigmann
katrin.weigmann@dzne.de
49-228-433-02263
Helmholtz Association of German Research Centres
Source:Eurekalert

Related biology news :

1. Malaria modeling and control focus of workshop
2. Malaria-infected cells stiffen, block blood flow
3. New study examines immunity in emerging species of a major mosquito carrer of malaria
4. Researchers link cerebral malaria to epilepsy, behavior disorders
5. UC Riverside cell biologist to investigate how malaria parasite multiplies in red blood cells
6. International malaria research consortium tackles deadly disease
7. Genetic markers offer new clues about how malaria mosquitoes evade eradication
8. Malaria research begins to bite
9. Malarias newest pathway into human cells identified
10. Novartis and collaborators discover novel antimalarial drug candidate
11. New methods, new math speed detection of drug-resistant malaria
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/18/2016)... -- --> --> Competitive ... Unmanned Vehicles, Physical infrastructure and Perimeter Surveillance & Detection Systems ... security market and the continuing migration crisis in the ... has led visiongain to publish this unique report, which ... defence & security companies in the border security market ...
(Date:3/14/2016)... 2016 http://www.apimages.com ) - ... - Renvoi : image disponible via AP Images ... --> DERMALOG, le leader de ... lecteurs d,empreintes digitales pour l,enregistrement des réfugiés en ... pour produire des cartes d,identité aux réfugiés. DERMALOG ...
(Date:3/9/2016)... NEW YORK , March 9, 2016 ... current and future states of the RNA Sequencing (RNA ... in segments such as instruments, tools and reagents, data ... Analyze various segments of the RNA-Sequencing market such ... RNA-Sequencing services Identify the main factors affecting each segment ...
Breaking Biology News(10 mins):
(Date:5/3/2016)... 2016 The report "Biochips ... Gene Expression) Lab-on-a-chip (IVD & POC, Proteomics), ... Centers), Fabrication Technology (Microarrays, Microfluidics) - Forecast ... is expected to reach USD 17.75 Billion ... 2015, growing at a CAGR of 18.4% ...
(Date:5/3/2016)... , ... May 03, 2016 , ... ... accessibility to unique bioresearch materials from laboratories across the globe, today announced the ... to increase the pace of research toward treatment and prevention measures for the ...
(Date:5/3/2016)... ... May 03, 2016 , ... Nashville ... IVF laboratories. A contingency of reproductive endocrinologists, including Dr. George Hill ... infertility and to help them build families. , Ovation Fertility is a nationwide ...
(Date:4/29/2016)... ... April 30, 2016 , ... The MIT bioLogic design team ... bioLogic team explored how bacterial properties can be applied to fabric and formed into ... which move in response to humidity change. The team harvested Natto cells and applied ...
Breaking Biology Technology: